Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.50 | N/A | -9.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.50 | N/A | -9.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed a cautious optimism about future growth. They emphasized their focus on long-term strategies and innovation.
We are focused on our long-term growth strategy despite current challenges.
Our commitment to innovation remains strong as we navigate this period.
The earnings report shows that 10X Genomics Inc faced challenges with its EPS, missing expectations. However, the stock rose by 3.10%, likely driven by investor optimism about the company's long-term growth strategy and commitment to innovation despite the current losses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BANCO BILBAO VIZCAYA ADR
Apr 29, 2024